Sugi Predict

Sugi Predict / Compounds / SCHEMBL2264435

SCHEMBL2264435

SCHEMBL2264435

Cc1ccc(C(=O)NC(C)(C)C)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ HDAC1 Q13547 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ MAPT P10636 1/20 0.53
▸ LMNA P02545 3/20 0.52
▸ TP53 P04637 1/20 0.52
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ CES2 O00748 1/20 0.50
▸ CES1 P23141 1/20 0.50
▸ MMP13 P45452 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17865779 0.91 LMNA (0.58) HDAC1MAPTLMNAHTTSMN1; SMN2
SCHEMBL1507761 0.88 HPGD (0.49) ALDH1A1GAAHDAC1HDAC6NPC1
SCHEMBL2522600 0.84 LMNA (0.53) ALDH1A1HDAC1MAPTLMNAHTT
SCHEMBL3716265 0.83 SRD5A2 (0.53) ALDH1A1GAALMNATP53HTT
SCHEMBL13762029 0.83 HDAC1 (0.67) HDAC1HDAC6NPC1RAB9AMAPT
SCHEMBL162828 0.83 TSHR (0.54) ALDH1A1MAPTLMNAHTTSMN1; SMN2
SCHEMBL13701770 0.83 HDAC2 (0.59) HDAC6MAPTLMNAHTTSMN1; SMN2
SCHEMBL25753418 0.83 LMNA (0.51) HDAC1RAB9AMAPTLMNAHTT
SCHEMBL11920177 0.82 ALDH1A1 (0.55) ALDH1A1GAAHDAC1HDAC6NPC1
SCHEMBL11845852 0.82 ALDH1A1 (0.55) ALDH1A1GAAHDAC1HDAC6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0755250-A4 BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS CENTAUR PHARMACEUTICALS INC (US) 2000-04-19 — — EP claimed
EP-0755250-A1 BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS CENTAUR PHARMACEUTICALS, INC. (US) 1997-01-29 — — EP claimed
US-5472983-A Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects CENTAUR PHARMACEUTICALS, INC. (US) 1995-12-05 — — US claimed
WO-1995028153-A1 BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS CENTAUR PHARMACEUTICALS, INC. (US) 1995-10-26 — — WO claimed
US-4496736-A ALKALINE HYDROLYSIS OF ALKYLACRBOXYLIC AMIDES BAYER AKTIENGESELLSCHAFT (DE) 1985-01-29 — — US claimed
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH & CIE (CH) 2026-03-12 — — US disclosed
CN-119192012-A Reductive amidation method of aryl fluorosulfonate and isocyanate 南京工业大学 2024-12-27 — — CN disclosed
CN-118834139-A Reductive amidation method of aryl sulfonium salt and isocyanate 南京工业大学 2024-10-25 — — CN disclosed
CN-113873884-B Arthropod control composition 弗门尼舍有限公司 2024-06-14 — — CN disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 — — WO disclosed
US-20230159488-A1 APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE Suzhou WEAST Biotechnology Co., Ltd. (CN) 2023-05-25 — — US disclosed
US-20220142157-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH SA (CH) 2022-05-12 — — US disclosed
EP-0695184-A1 HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1996-02-07 — — EP disclosed
US-5472983-A Neurodegenerative conditions associated with dopamine depletion, e.g. Alzheimer's, Parkinson's, multiple sclerosis, Huntington's amyltrophic lateral sclerosis and vision defects CENTAUR PHARMACEUTICALS, INC. (US) 1995-12-05 — — US disclosed
WO-1995028153-A1 BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS CENTAUR PHARMACEUTICALS, INC. (US) 1995-10-26 — — WO disclosed
WO-1994015906-A1 HIV PROTEASE INHIBITORS AND THEIR PREPARATION AGOURON PHARMACEUTICALS, INC. (US) 1994-07-21 — — WO disclosed
WO-1994015608-A1 HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1994-07-21 — — WO disclosed
US-4496736-A ALKALINE HYDROLYSIS OF ALKYLACRBOXYLIC AMIDES BAYER AKTIENGESELLSCHAFT (DE) 1985-01-29 — — US disclosed
EP-0068219-B1 PROCESS FOR THE SIMULTANEOUS PREPARATION OF CARBOXYLIC ACIDS AND N-TERT,-ALKYL AMINES BAYER AG (DE) 1984-08-29 — — EP disclosed
EP-0068219-A1 Process for the simultaneous preparation of carboxylic acids and N-tert,-alkyl amines BAYER AG (DE) 1983-01-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION CNOT9, MSL1, MT-CO2 ALDH1A1 3224/4885GAA 4737/4885HDAC1 2857/4885
US-20230159488-A1 APPLICATION OF HETEROCYCLIC COMPOUND CONTAINING AT LEAST TWO SULFUR ATOMS IN PREPARING NANO-VACCINE AND PREPARED NANO-VACCINE CD4, NFATC1, CTSA ALDH1A1 4510/4885GAA 21/4885HDAC1 1628/4885
US-20220142157-A1 ARTHROPOD CONTROLLING COMPOSITION AGO2, NOP2, FBL ALDH1A1 3272/4885GAA 1982/4885HDAC1 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.